Cargando…

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?

BACKGROUND: Stage III Non-small cell lung cancer (NSCLC) is a heterogenous disease with novel treatment options. Recently, immunotherapy has attracted a lot of attention for advanced NSCLC. OBJECTIVE: The objective of our study was to assess the efficacy and safety of neoadjuvant immuno-chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yuanshan, Tang, Dongfang, Gao, Wen, Zhang, Huibiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018103/ https://www.ncbi.nlm.nih.gov/pubmed/35449550 http://dx.doi.org/10.3389/fsurg.2022.843987

Ejemplares similares

Prognostic value of final pathological stage in colon adenocarcinoma after neoadjuvant chemotherapy: A propensity score-matched study
por: Xiang, Meijuan, et al.
Publicado: (2022)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

The Independent Prognostic Effect of Lymph Node Dissection on Patients With Stage IA NSCLC With Different T Stages
por: Zhao, Dechang, et al.
Publicado: (2021)

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2021)

Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration
por: Chen, Chunji, et al.
Publicado: (2022)

Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer
por: Zhang, Lin, et al.
Publicado: (2020)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
por: Labori, Knut Jørgen
Publicado: (2022)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer
por: Yang, Gaohua, et al.
Publicado: (2022)

Decrease in Blood Neutrophil-to-Lymphocyte Ratio Indicates Better Survival After Neoadjuvant Chemotherapy in Patients With Advanced Gastric Cancer
por: Liu, Ziyi, et al.
Publicado: (2021)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
por: He, Yang, et al.
Publicado: (2023)

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
por: Zhou, Zhen, et al.
Publicado: (2022)

Association of serum reproductive hormones changes after neoadjuvant chemotherapy with hormone receptors expression alterations and survival outcomes in breast cancer
por: Lan, Ailin, et al.
Publicado: (2022)

Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis
por: Zhai, Yuhao, et al.
Publicado: (2023)

Clinicopathological Features of Stage I–III Colorectal Cancer Recurrence Over 5 Years After Radical Surgery Without Receiving Neoadjuvant Therapy: Evidence From a Large Sample Study
por: Luo, Dakui, et al.
Publicado: (2021)

Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics †
por: Chiappetta, Marco, et al.
Publicado: (2022)

The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis
por: Liu, Jinzhao, et al.
Publicado: (2022)

Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation
por: Bunch, Connor M., et al.
Publicado: (2022)

Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and NSCLC Progression:Evidence From Bioinformatics Analysis
por: Yao, Yuanshan, et al.
Publicado: (2022)

Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial
por: Li, Ziyu, et al.
Publicado: (2018)

Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
por: Yu, Deguo, et al.
Publicado: (2022)

Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study
por: Li, Yijun, et al.
Publicado: (2022)

Immediate Breast Reconstruction After Neoadjuvant Chemotherapy: Factors Associated With Surgical Selection and Complications
por: Chi, Weiru, et al.
Publicado: (2023)

Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy
por: TAKAHASHI, RYUJI, et al.
Publicado: (2013)

Preoperative Low Prealbumin Is Associated With Recurrence in Patients With Stage II/III Gastric Cancer After Laparoscopic D2 Gastrectomy
por: Gao, Chun, et al.
Publicado: (2022)

Complete Video-Assisted Thoracoscopic Surgery and Traditional Open Surgery for Elderly Patients With NSCLC
por: Mao, Yi, et al.
Publicado: (2022)

Prospective Evaluation of Response Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
por: A., Ashok, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience
por: Nguyen, Thanh-Tuan, et al.
Publicado: (2018)

Comparison of Four Lymph Node Staging Systems in Gastric Adenocarcinoma after Neoadjuvant Therapy – A Population-Based Study
por: Lai, Hongkun, et al.
Publicado: (2022)

Predictive value of immuno-inflammatory and nutritional measures modulated by neoadjuvant chemotherapy on the response of neoadjuvant chemotherapy and long-term outcomes in patients with esophageal cancer
por: Ishibashi, Yusuke, et al.
Publicado: (2020)

Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients
por: Guo, Qiang, et al.
Publicado: (2022)

An individualized nomogram for predicting and validating spread through air space (STAS) in surgically resected lung adenocarcinoma: a single center retrospective analysis
por: Wang, Jing, et al.
Publicado: (2023)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Construction and validation of a nomogram model to predict the overall survival rate of esophageal cancer patients receiving neoadjuvant chemotherapy: A population-based study
por: Yang, Ying, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
por: Zaher, Haidi Abd El, et al.
Publicado: (2023)

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
por: Zhu, Xinsheng, et al.
Publicado: (2022)

Distal end of Double-J ureteral stent position on ureteral stent-related symptoms: A systematic review and meta-analysis
por: Bao, Xingjun, et al.
Publicado: (2022)

The efficacy of peripheral nerve block on postoperative catheter-related bladder discomfort in males: A systematic review and meta-analysis
por: Bao, Xingjun, et al.
Publicado: (2023)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_84j92o8o60v9up31qq1iu3d7c5